法国内分泌协会关于免疫治疗的内分泌副反应指导意见解读  

Interpretation of French Endocrine Society Guidance on endocrine side effects of immunotherapy

作　　者：吴绮楠 Wu Qinan(Endocrinology and Nephrology Department,Chongqing University Cancer Hospital)

机构地区：[1]重庆大学附属肿瘤医院内分泌肾脏病科

出　　处：《重庆医科大学学报》2019年第12期1529-1534,F0002,共7页Journal of Chongqing Medical University

基　　金：国家自然科学基金资助项目(编号:81370885);西南医院军事医学科技创新计划一般资助项目(编号:SWH2017YBXM-12)

摘　　要：由于免疫检查点抑制剂(immune checkpoint inhibitor,ICPI)在临床上使用频率增高及适应证不断扩展,对于内分泌及肿瘤医师来说,应该知道如何去诊断和治疗ICPI内分泌方面的副反应。鉴于此,法国内分泌学会起草了关于免疫治疗相关内分泌副反应的指导意见。该指导意见介绍了关于ICPI内分泌副反应的研究进展,并就ICPI导致内分泌副反应的筛查、管理、监控方法提出共识意见。本文就该指导意见作一解读。The wildly use of immunological checkpoint inhibitors(ICPI)in clinical practice and the indications expanding make endocrinologists and oncologists focused on the diagnose and treat the endocrine side effects of ICPI.The French Society of Endocrinology drafted guidance on Immunotherapy-related endocrine side effects.The guidance introduced research on endocrine side effects of ICPI,and provided consensus on the screening,management and monitoring of endocrine side effects which caused by ICPI.Here we provide an interpretation of this guidance.

关 键 词：免疫治疗 免疫检查点抑制剂 内分泌副反应 

分 类 号：R392.6[医药卫生—免疫学]